Pfizer will combine its off-patent drug business with Mylan

By

Pfizer will combine its off-patent drug business with Mylan

The deal will result in Pfizer shareholders owning most of the new company with Mylan’s shareholders owning slightly more than 40%.

Source: Business News –

MustHaves.LA a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for us to earn fees by linking to Amazon.com and affiliated sites.